| 摘要 |
The invention relates to the use of substituted benzamide derivatives of Formula I: Wherein: A1 and A2 are -N or -CH, so that if A1 is -N, then A2 is -CH and If A2 is -N, then A1 is -CH; R is a hydrogen atom, or represents branched or unbranched -(C1-C3)-alkyl, -(C1-C3)-alkyl, wherein one, two or three hydrogen atoms may be substituted by a halogen or hydroxyl, -(C1 -C3)-O-(C1-C3), -(C1-C3)-O-(C1-C3), wherein one, two or three hydrogen atoms may be substituted by a halogen, or R is a group wherein R3 and R4 both together or independently are halogen, hydroxyl, -(C1-C3)alkyl, wherein one, two or three hydrogen atoms may be substituted by a halogen or hydroxyl, -O-(C1-C3)-alkyl, -O-(C1-C3)-alkyl, wherein one, two or three hydrogen atoms may be substituted by a halogen, -O-(C1-C3)-O-(C1-C3), -O-(C1-C3)-O-(C1-C3), wherein one, two or three hydrogen atoms may be substituted by a halogen; R1 and R2 both together or independently are halogen, hydroxyl, -(C1-C3)-alkyl, -(C1-C3)-alkyl, wherein one, two or three hydrogen atoms may be substituted by a halogen or hydroxyl, -O- (C1-C3)-alkyl, -O-(C1-C3)-alkyl, wherein one, two or three hydrogen atoms may be substituted by a halogen, -Ο-(C1-C3)-Ο-(C1-C3), -0-(C1C3)-O-(C1C3), wherein one, two or three hydrogen atoms may be substituted by a halogen, their pharmaceutically acceptable salts, isomers or mixtures thereof as in vitro selective MAO-B inhibitors. The substituted benzamide derivatives of Formula I, their pharmaceutically acceptable salts, isomers or mixtures thereof are useful for the manufacture of a medicament for prevention and treatment of acute and chronic neurological disorders, cognitive and neurodegenerative diseases, more precisely for the manufacture of a medicament for prevention and treatment of neurodegenerative disorders such as Parkinson's Disease and Alzheimer's Disease. |
